ArticleDiscover oncology2026

PHC2 as a novel predictive biomarker and therapeutic target for cisplatin resistance in lung adenocarcinoma.

Xue Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.